Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6893076 | 0.94 | CYP3A4 (0.46) | CYP3A4SMN1; SMN2NR1I2PPARAALDH1A1 | |
| SCHEMBL23539171 | 0.92 | PPARA (0.47) | CYP3A4SMN1; SMN2PPARAALDH1A1RECQL | |
| SCHEMBL11091498 | 0.88 | L3MBTL1 (0.46) | CYP3A4SMN1; SMN2PPARAL3MBTL1LTA4H | |
| SCHEMBL6259760 | 0.86 | SMN1; SMN2 (0.41) | CYP3A4SMN1; SMN2PPARAALDH1A1L3MBTL1 | |
| SCHEMBL6255661 | 0.77 | HRH3 (0.49) | CYP3A4SMN1; SMN2NR1I2PPARAALDH1A1 | |
| SCHEMBL14524692 | 0.77 | SMN1; SMN2 (0.47) | CYP3A4SMN1; SMN2PPARAALDH1A1L3MBTL1 | |
| SCHEMBL21414837 | 0.75 | NQO1 (0.56) | SMN1; SMN2ALDH1A1RECQLL3MBTL1LTA4H | |
| SCHEMBL21414840 | 0.75 | PPARA (0.45) | SMN1; SMN2PPARAALDH1A1RECQLL3MBTL1 | |
| SCHEMBL23539112 | 0.75 | PPARA (0.46) | CYP3A4SMN1; SMN2PPARAALDH1A1L3MBTL1 | |
| SCHEMBL23539109 | 0.75 | PPARA (0.46) | CYP3A4SMN1; SMN2PPARAALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005068410-A1 | ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2005-07-28 | — | — | WO | claimed |
| US-20040192771-A1 | Ether compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2004-09-30 | — | — | US | claimed |
| US-20030018013-A1 | Ether compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2003-01-23 | — | — | US | claimed |
| WO-2005068410-A1 | ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| US-6713507-B2 | CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS; ALZHEIMER'S DISEASE | ESPERION THERAPEUTICS, INC. | 2004-03-30 | — | — | US | disclosed |
| EP-1351916-A2 | ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002030863-A2 | ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018013-A1 | Ether compounds and compositions for cholesterol management and related uses | GPR119, PNLIP, NR1H2 | CYP3A4 361/4885SMN1; SMN2 2495/4885NR1I2 221/4885 |
| US-20040192771-A1 | Ether compounds and compositions for cholesterol management and related uses | GPR119, PNLIP, NR1H2 | CYP3A4 361/4885SMN1; SMN2 2495/4885NR1I2 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.